# Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

> **NCT02525133** · PHASE3 · COMPLETED · sponsor: **Innocoll** · enrollment: 319 (actual)

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** XaraColl
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02525133
- **Lead sponsor:** Innocoll
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-05
- **Primary completion:** 2016-04-22
- **Final completion:** 2016-04-22
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525133, "Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02525133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*